Publications 

  • Philis-Tsimikas A, Lane W, Pedersen-Bjergaard U, et al. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL. Diabetes Obes Metab. 2020;22(5):779‐787. doi:10.1111/dom.13954

  • Lane WS, Favaro E, Rathor N, et al. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) [published online ahead of print, 2020 Mar 24]. Diabetes Care. 2020;dc192232. doi:10.2337/dc19-2232 
 
  • Sacha JM, Lane WS. Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018;41:2471-2479. Diabetes Care. 2019;42(6):e96‐e97. doi:10.2337/dc19-0176
 
  • Klonoff DC, Evans ML, Lane W, et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019;21(4):961‐967. doi:10.1111/dom.13610
 
  • DeVries JH, Bailey TS, Bhargava A, et al. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019;21(3):622‐630. doi:10.1111/dom.13565
 
  • Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018;41(9):1970‐1980. doi:10.2337/dc18-0343
 
  • Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables [published correction appears in J Med Econ. 2018 May;21(5):542]. J Med Econ. 2018;21(2):144‐151. doi:10.1080/13696998.2017.1384383
 
  • Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017;318(1):33‐44. doi:10.1001/jama.2017.7115
 
  • Lane W. SGLT-2 INHIBITORS AS ADJUNCT THERAPY IN TYPE 1 DIABETES: REASON FOR HOPE AND CAUTION. Endocr Pract. 2016;22(3):371‐373. doi:10.4158/EP151096.CO
 
  • Grunberger G, Abelseth JM, Bailey TS, et al. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014;20(5):463‐489. doi:10.4158/EP14145.PS
  • ​Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014;20(4):285‐292. doi:10.4158/EP13287.OR

  • Lane W, Weinrib S, Rappaport J, Hale C. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab. 2014;16(9):827‐832. doi:10.1111/dom.12286
 
  • Lane WS, Weinrib SL, Rappaport JM, Hale CB, Farmer LK, Lane RS. The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Endocr Pract. 2013;19(2):196‐201. doi:10.4158/EP12226.OR
 
  • Weinrib SL, Lane WS, Rappaport JM. Successful management of differentiated thyroid cancer in a community-based endocrine practice. Endocr Pract. 2012;18(2):170‐178. doi:10.4158/EP11144.OR
 
  • Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technology & Therapeutics. 2011 May;13(5):592-595. DOI: 10.1089/dia.2010.0221
 
  • Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance [published correction appears in Endocr Pract. 2010 Nov-Dec;16(6):1082]. Endocr Pract. 2010;16(5):778‐784. doi:10.4158/EP10014.OR
 
  • Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes [published correction appears in N Engl J Med. 2010 Sep 9;363(11):1092]. N Engl J Med. 2010;363(4):311‐320. doi:10.1056/NEJMoa1002853
 
  • Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin?. Endocr Pract. 2009;15(1):71‐79. doi:10.4158/EP.15.1.71
 
  • Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006;12(3):251‐256. doi:10.4158/EP.12.3.251
 
  • Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28(3):533‐538. doi:10.2337/diacare.28.3.533
​
  • Tanenberg R, Bode B, Lane W, et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521‐1526. doi:10.4065/79.12.1521
Home     Our Providers     Research     Contact Us     FAQ     Patient Portal 

Mountain Diabetes & Endocrine Center
1998 Hendersonville Rd. Bldg. 31
Asheville, NC 28803
Phone: (828)-684-9588 Fax clinic: (828)-684-9626 Fax Research: (828)-684-9607